The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease
Brage Brakedal, Christian Dölle, Frank Riemer, Yilong Ma, Gonzalo S. Nido, Geir Skeie, Alexander R. Craven, Thomas Schwarzlmüller, Njål Brekke, Joseph Diab, Lars J. Sverkeli, Vivian Skjeie, Kristin N. Varhaug, Ole‐Bjørn Tysnes, Shichun Peng, Kristoffer Haugarvoll, Mathias Ziegler, Renate Grüner, David Eidelberg, Charalampos Tzoulis
Topics & Concepts
NAD+ kinaseNicotinamide adenine dinucleotideNeuroprotectionNicotinamide phosphoribosyltransferaseMetabolomeParkinson's diseaseMedicineCerebrospinal fluidInternal medicineEndocrinologyPharmacologyNicotinamideChemistryBiochemistryMetaboliteDiseaseEnzymeParkinson's Disease Mechanisms and TreatmentsCalcium signaling and nucleotide metabolismAutophagy in Disease and Therapy